Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial.

Saved in:
Bibliographic Details
Title: Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial.
Authors: Ragni MV; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA. Electronic address: ragni@pitt.edu., Rothenberger SD; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Center for Research on Health Care, University of Pittsburgh, Pittsburgh, PA, USA., Feldman R; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Center for Research on Health Care, University of Pittsburgh, Pittsburgh, PA, USA., Nance D; Banner MD Anderson Cancer Center, Gilbert, AZ, USA., Leavitt AD; University of California, San Francisco, CA, USA., Malec L; Versiti Blood Research Institute, Milwaukee, WI, USA., Kulkarni R; Michigan State University, East Lansing, MI, USA., Sidonio R Jr; Emory University, Atlanta, GA, USA., Kraut E; The Ohio State University, Columbus, OH, USA., Lasky J; Cure 4 the Kids, Las Vegas, NV, USA., Pruthi R; Mayo Clinic, Rochester, MN, USA., Angelini D; Cleveland Clinic, Cleveland, OH, USA., Philipp C; Rutgers University, New Brunswick, NJ, USA., Hwang N; Center for Inherited Bleeding Disorders, Orange, CA, USA., Wheeler AP; Vanderbilt University, Nashville, TN, USA., Seaman C; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA., Machin N; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA., Xavier F; Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA; Children's Hospital of Pittsburgh, Pittsburgh, PA, USA., Meyer M; Vitalant Coagulation Laboratory, Pittsburgh, PA, USA., Bellissimo D; Department of Pathology, Magee Women's Hospital Clinical Genomics Laboratory, Pittsburgh, PA, USA., Humphreys G; Department of Pathology, Magee Women's Hospital Clinical Genomics Laboratory, Pittsburgh, PA, USA., Smith KJ; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Center for Research on Health Care, University of Pittsburgh, Pittsburgh, PA, USA., Merricks EP; Department of Pathology and Laboratory Medicine and the UNC Blood Research Center, School of Medicine, University of North Carolina, Chapel Hill, NC, USA., Nichols TC; Department of Pathology and Laboratory Medicine and the UNC Blood Research Center, School of Medicine, University of North Carolina, Chapel Hill, NC, USA., Ivanco D; Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA., Vehec D; Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA., Koerbel G; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Center for Research on Health Care, University of Pittsburgh, Pittsburgh, PA, USA., Althouse AD; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Center for Research on Health Care, University of Pittsburgh, Pittsburgh, PA, USA.
Source: The Lancet. Haematology [Lancet Haematol] 2023 Aug; Vol. 10 (8), pp. e612-e623. Date of Electronic Publication: 2023 Jun 26.
Publication Type: Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2352-3026
DOI:10.1016/S2352-3026(23)00119-9